NDA 209510 · Lxo Ireland
Barhemsys
Amisulpride · Intravenous · Dopamine-2 Receptor Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Sep 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Feb 26, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
75
14 Phase 3, 3 recruiting
FAERS reports
6,123
6,004 serious, 796 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 17, 2026.
BARHEMSYS ® is indicated in adults for: prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. BARHEMSYS is a dopamine-2 (D 2 ) antagonist indicated in adults for: Prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. ( 1 ) Treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. ( 1 )
Mechanism: Amisulpride is a selective dopamine-2 (D 2 ) and dopamine-3 (D 3 ) receptor antagonist. D 2 receptors are located in the chemoreceptor trigger zone (CTZ) and respond to the dopamine released from the nerve endings. Activation of CTZ relays stimuli to the vomiting center which is involved in emesis. Studies in multiple species indicate that D 3 receptors in the area postrema also play a role in emesis. Studies conducted in ferrets have shown that amisulpride inhibits emesis caused by apomorphine, with an estimated ED 50 of less than 1 mcg/kg, subcutaneously; and inhibits cisplatin-induced...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- BARHEMSYS · AMISULPRIDE 10MG/4ML (2.5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- BARHEMSYS · AMISULPRIDE 5MG/2ML (2.5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Amisulpride" as an intervention, any sponsor and status, largest first.
- Phase IIIb Study of APD421 in Combination as PONV ProphylaxisPivotal-lookingCompleted
Acacia Pharma LtdIndustry
NCT02337062 · 1,147 participants · Start Feb 2015 · Primary completion Sep 2015
Drug: APD421; Placebo · For: PONV
Sites: Sheffield, Alabama; San Francisco, California; Miami, Florida · 25 sites in all
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)Pivotal-lookingCompleted
Shanghai Mental Health CenterAcademic, hospital or other
NCT03510325 · 762 participants · Start Feb 12, 2019 · Primary completion Sep 27, 2023
Drug: Phase 1: Olanzapine; Phase 1: Risperidone and 7 more · For: Schizophrenia
Sites: Beijing, China; Wuhan, China; Nanjing, China · 7 sites in all
- Amisulpride Injection for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic SurgeryPivotal-lookingNot yet recruiting
Qianfoshan HospitalAcademic, hospital or other
NCT07891312 · 718 participants (planned) · Start Nov 15, 2026 · Primary completion Jan 1, 2028
Drug: Amisulpride; Ondansetron · For: PONV
- Study of APD421 as PONV Treatment (Prior Prophylaxis)Pivotal-lookingCompleted
Acacia Pharma LtdIndustry
NCT02646566 · 705 participants · Start Mar 2016 · Primary completion Jan 2017
Drug: APD421; Placebo · For: Postoperative Nausea and Vomiting
Sites: Miami, Florida; Durham, North Carolina; Winston-Salem, North Carolina · 8 sites in all
- Study of APD421 as PONV Treatment (no Prior Prophylaxis)Pivotal-lookingCompleted
Acacia Pharma LtdIndustry
NCT02449291 · 568 participants · Start Sep 2015 · Primary completion Jul 2016
Drug: APD421; Placebo · For: Postoperative Nausea and Vomiting
Sites: Miami, Florida; Columbus, Ohio; Strasbourg, France · 4 sites in all
- A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.Pivotal-lookingStatus unknown
Qilu Pharmaceutical (Hainan) Co., Ltd.Industry
NCT05822713 · 516 participants (planned) · Start Apr 29, 2023 · Primary completion Aug 31, 2023
Drug: Amisulpride; Amisulpride Placebo · For: PONV
- SWitching to Abilify Trial (SWAT)Pivotal-lookingCompleted
Korea Otsuka Pharmaceutical Co., Ltd.Industry
NCT00304616 · 500 participants · Start Oct 2004 · Primary completion Jun 2006
Drug: Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone · For: Schizophrenia
Sites: Seoul, South Korea
- Optimization of Treatment and Management of Schizophrenia in EuropePivotal-lookingCompleted
Rene KahnAcademic, hospital or other
NCT01248195 · 479 participants · Start May 2011 · Primary completion Apr 2016
Drug: Amisulpride open label; 6-week amisulpride double blind treatment and 2 more · For: Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder
Sites: Melbourne, Australia; Innsbruck, Austria; Leuven, Belgium · 26 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective872
- drug interaction483
- weight increased446
- toxicity to various agents416
- neutropenia408
- schizophrenia339
- off label use333
- leukopenia316
- akathisia307
- extrapyramidal disorder302
- electrocardiogram qt prolonged283
- suicide attempt282
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 49 |
| 2006 | 65 |
| 2007 | 79 |
| 2008 | 75 |
| 2009 | 111 |
| 2010 | 162 |
| 2011 | 189 |
| 2012 | 194 |
| 2013 | 229 |
| 2014 | 224 |
| 2015 | 223 |
| 2016 | 216 |
| 2017 | 287 |
| 2018 | 376 |
| 2019 | 451 |
| 2020 | 379 |
| 2021 | 397 |
| 2022 | 481 |
| 2023 | 469 |
| 2024 | 635 |
| 2025 | 467 |
| 2026 | 331 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. · Lancet 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S, Cipriani A, Spineli L, et al. · Lancet 2013 · Comparative Study, Meta-Analysis
- Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S, Crippa A, Siafis S, et al. · Am J Psychiatry 2020 · Meta-Analysis
- Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
Pillinger T, McCutcheon RA, Vano L, et al. · Lancet Psychiatry 2020 · Comparative Study, Network Meta-Analysis
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S, Rücker G, Eberhart LH, et al. · Cochrane Database Syst Rev 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- What does the PANSS mean?
Leucht S, Kane JM, Kissling W, et al. · Schizophr Res 2005 · Clinical Trial, Comparative Study
Sponsor: Lxo Ireland
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.